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ABSTRACT
Objectives: To assess the difference in direct medical costs between
on-demand (OD) treatment with esomeprazole (E) 20 mg and continuous
(C) treatment with E 20 mg q.d. from a clinical practice view in patients
with gastroesophageal reﬂux disease (GERD) symptoms.
Methods: This open, randomized study (ONE: on-demand Nexium evalu-
ation) compared two long-term management options with E 20 mg in
endoscopically uninvestigated patients seeking primary care for GERD
symptoms who demonstrated complete relief of symptoms after an initial
treatment of 4 weeks with E 40 mg. Data on consumed quantities of all
cost items were collected in the study, while data on prices during the time
of study were collected separately. The analysis was done from a societal
perspective.
Results: Forty-nine percent (484 of 991) of patients randomized to the
OD regimen and 46% (420 of 913) of the patients in the C group had at
least one contact with the investigator that would have occurred
nonprotocol-driven. The difference of the adjusted mean direct medical
costs between the treatment groups was CHF 88.72 (95% conﬁdence
interval: CHF 41.34–153.95) in favor of the OD treatment strategy
(Wilcoxon rank-sum test: P < 0.0001). Adjusted direct nonmedical
costs and productivity loss were similar in both groups.
Conclusions: The adjusted direct medical costs of a 6-month OD treat-
ment with esomeprazole 20 mg in uninvestigated patients with symptoms
of GERD were signiﬁcantly lower compared with a continuous treatment
with E 20 mg once a day. The OD therapy represents a cost-saving
alternative to the continuous treatment strategy with E.
Keywords: cost-effectiveness, costs, economic evaluation, esomeprazole,
gastroesophageal reﬂux disease, proton pump inhibitor.
Introduction
Reﬂux disease is a growing public health problem. Not only does
this condition cause multiple clinical problems, it is also associ-
ated with a large economic burden.
In Switzerland, the prevalence of reﬂux disease in Swiss adults
was estimated at 17.6% (95% conﬁdence interval [CI] 15.6–
19.7%) or 993,000 individuals [3]. The diseasewasmore frequent
in the French-speaking part of the country and rising with age,
while being equally distributed among the sexes. Regular treat-
ment with medication was reported by 38.0% of the individuals
with gastroesophageal reﬂux disease (GERD) symptoms. Reﬂux-
induced general practitioner ofﬁce visits during the last year were
reported by 25.9%. On average, there were 0.84 general practi-
tioner consultations, 0.19 specialist consultations, and 0.01 hos-
pitalizations annually. Mean direct medical costs, dominated by
medication costs, were CHF 185 per patient-year (95% CI CHF
140–230) or CHF 0.18 billion per year in Switzerland. Total costs
amounted to CHF 234 (95% CI CHF 185–284), thus the total
costs of reﬂux disease in Switzerland amounted to CHF 0.23
billion per year. In consequence, the direct medical costs of reﬂux
disease accounted for approximately 0.5% of the total Swiss
health-care expenditures.
Esomeprazole, the S-enantiomere of omeprazole, is a proton
pump inhibitor that produced an increased duration and level of
inhibition of gastric acid secretion than pantoprazole, lansopra-
zole, rabeprazole and omeprazole in different studies [4–6].
Patients treated with esomeprazole experienced a rapid relief
of their GERD symptoms [7–10]. Because of stronger acid
suppression, esomeprazole is a promising drug for patient-driven
treatment (i.e., on-demand treatment, according to the patient’s
own judgment).
In clinical practice, patients with GERD symptoms are often
treated empirically with proton pump inhibitors without investi-
gation by, for example, endoscopy. When the patient is free from
GERD symptoms, there are two main options available to the
treating physician for the long-term management of the disease.
The physician can prescribe continuous daily treatment or
on-demand treatment as required to control symptoms.
Given the advent of highly efﬁcacious medications and
trends suggesting an increase in disease prevalence and inci-
dence, it is necessary to appraise the costs and the consequences
of GERD treatment. Most importantly, it is yet unknown what
the economic difference is between a long-term maintenance
treatment strategy and an on-demand treatment strategy. The
present publication focuses on the comparison of the two treat-
ment options concerning health economic aspects.
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Economic Study Perspective
The types of costs that should be included in an economic evalu-
ation depend on the perspective adopted [11]. It is generally
recommended that a societal perspective should be adopted, and
that all types of costs should be included. First, there are direct
costs, which occur as a result of changes in health-care utilization
because of an intervention. Direct costs can be divided into
medical, such as costs borne by the health-care provider (e.g.,
drugs, health-care visits, tests), and nonmedical, such as costs
borne by the patient (e.g., transport to visits, housekeeping,
home modiﬁcations). Second, there are indirect costs, which are
costs for changes in productivity owing to morbidity and mor-
tality. Examples of typical indirect costs are loss of production
because of absenteeism from work and early retirement.
Objectives
The primary objective of this prospective health economic study
was to assess the difference in direct medical costs between
on-demand treatment with esomeprazole 20 mg and continuous
treatment with esomeprazole 20 mg q.d. from a clinical practice
view in patients with GERD symptoms.
The secondary objectives were to measure direct nonmedical
costs and indirect costs during the maintenance phase, to
measure patient satisfaction with treatment strategy, to assess
time to ﬁrst relapse, deﬁned as time to the patient’s contact to the
investigator because of need for change of treatment because of
insufﬁcient control of symptoms, and to assess symptoms at each
study visit.
Methods
We conducted an open-label, randomized, multicenter study
(ONE: on-demand Nexium [AstraZeneca, London, UK] evalua-
tion) comparing the two long-term management options with
esomeprazole 20 mg—continuous daily or on-demand treatment
during 26 weeks—in endoscopically uninvestigated patients
seeking primary care in Switzerland for symptoms suggestive of
GERD who demonstrated complete relief of symptoms after an
initial treatment of 4 weeks with esomeprazole 40 mg.
The study was intended to be naturalistic in accordance with
health economic methodology while still maintaining control of
events where possible. An open study design is in accordance
with treatment in clinical practice, where both the treating phy-
sician and the patient are aware of the treatment regimen. Costs
were assessed during the whole maintenance phase, including
costs following an endoscopy, as well as costs because of a
patient or investigator-driven decision that the patient should no
longer abide with the study therapy.
Male and female patients (18 years of age) seeking primary
care for symptoms suggestive of GERD (heartburn as the pre-
dominant symptom with or without acid regurgitation; for 3
days or more during the last 7 days), were enrolled into the study
and had an initial treatment course for 4 weeks with esomepra-
zole 40 mg q.d. after having given written informed consent.
The main exclusion criteria were as follows: Existence of
any signiﬁcant “alarm symptoms,” such as unintentional weight
loss, gastrointestinal bleeding, dysphagia, jaundice, or any other
sign indicating serious or malignant disease. Patients with
known history of complications of GERD, such as Barrett’s
esophagus, esophageal stricture, ulcer, or signiﬁcant dysplastic
changes in the esophagus and or a history of esophageal,
gastric, or duodenal surgery were excluded. Excluded from the
study were patients with current or historical evidence of irri-
table bowel syndrome, Zollinger-Ellison syndrome, primary
esophageal motility disorder(s), gastric or duodenal ulcers
within the last 3 months, malabsorption, unstable diabetes mel-
litus, or cerebrovascular disease. Patients in need for continuous
concurrent therapy of diazepam, phenytoin, or warfarin were
also excluded. Pregnancy and lactation were also exclusion cri-
teria. After this initial 4-week treatment course with esomepra-
zole 40 mg, the asymptomatic patients (deﬁned as patients with
complete resolution of symptoms of not more than 1 day, with
mild symptoms during the last 7 days before the visit) continued
with the study. Patients with persistent symptoms after 4 weeks
left the study and were treated according to routine clinical
procedures.
Patients found to meet all the inclusion criteria and none of
the exclusion criteria at the end of the initial treatment course
were randomized in equal proportions to continuous treatment
with esomeprazole 20 mg q.d. or on-demand treatment with
esomeprazole 20 mg. For the randomization, a centrally com-
piled, computer-generated list was used, which was based on a
block size of four. Each site received a kit consisting of a list of
randomization numbers and sealed randomization envelopes for
four patients. The investigator was instructed to consecutively
allocate the lowest available randomization number, but open the
randomization envelopes containing the information on the allo-
cated treatment group only at randomization. It had been
planned that each site would recruit four patients (or an exact
multiple of four).
Each patient in the continuous treatment arm was instructed
to take one tablet once daily. In the on-demand arm, the patient
was instructed to take one tablet daily if needed for the relief of
heartburn and to stop when the heartburn is adequately con-
trolled. The study drugs were packed in bottles, and every patient
received in total two bottles of 100 tablets esomeprazole 20 mg
free of charge. The distribution schedule of the study drugs from
general practitioner to patient was at the discretion of the general
practitioner, i.e., the treating physician decided when to distrib-
ute study drugs and whether to distribute them all at once or at
several occasions. Compliance was determined by counting the
tablets returned by the patient.
Patients were instructed to contact the center if they experi-
enced symptom relapse (i.e., need for change of therapy in the
on-demand or continuous treatment groups). In such situations,
the patients were given a 4-week treatment course with esome-
prazole 40 mg q.d. supplied to the patient at unscheduled visits
necessary for this event. If symptom-free at the end of this treat-
ment course, the patients continued the long-term treatment to
which they were originally allocated. Patients with persisting
symptoms remained in the study, but were treated at the discre-
tion of the investigator. Patients leaving the study prematurely at
any time after randomization were followed with regard to costs
for the remainder of the study. Endoscopy could be carried out at
any time during the long-term treatment phase at the discretion
of the investigator.
During the maintenance phase, there was a scheduled visit
only at study completion, while unscheduled visits were made in
accordance with treatment in clinical practice and guided by the
patient’s need for therapy or change of therapy. At each visit after
randomization, the physician assessed whether the contact would
have occurred in clinical practice. Telephone interviews with each
patient to collect GERD-related information on health economic
data, patient satisfaction, and symptoms were conducted every 5
to 6 weeks, resulting in three to four interviews per patient
during the maintenance phase. A nonmedical but trained inter-
viewer, who was not allowed to give any medical advice to the
patient, carried out the telephone interviews by asking speciﬁc
questions to collect the study information.
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Clinical Assessment
GERD symptoms. At each visit, the presence of heartburn and
regurgitation during the past 7 days before the visit was assessed
retrospectively by the investigator in a standardized manner.
These symptoms were classiﬁed as: none, mild (awareness of
symptoms, but easily tolerated), moderate (discomfort sufﬁcient
to cause interference with normal activities), and severe (incapaci-
tating, with inability to perform normal activities).
Frequency of heartburn was recorded at the beginning and at
the end of the initial symptom treatment course as the number of
days with episodes during the last 7 days.
Because on-demand treatment is symptom-driven, more
symptoms were expected to be reported in this group as com-
pared with the continuous treatment group.
Patient satisfaction. Patient satisfaction was measured using a
7-point Likert scale (completely satisﬁed, very satisﬁed, quite
satisﬁed, satisﬁed, dissatisﬁed, very dissatisﬁed, and completely
dissatisﬁed). Patients were asked to choose the response that
would best describe the degree of their satisfaction/dissatisfaction
with the way their heartburn was treated during the study based
on the question how satisﬁed or dissatisﬁed the patient was with
the way his/her heartburn was treated during the study. The
answer to this question was recorded at each visit except the ﬁrst
one and during telephone interviews during the maintenance
phase.
Safety Assessments
Adverse events. In this trial, only seriouse adverse events (SAEs)
and adverse events (AEs) leading to the discontinuation of the
study drug or other important AEs according to the investigator
occurring from the ﬁrst administration of the study drug until the
end of the study were recorded.
Health economic assessments. Data on consumed quantities of
all cost items (e.g., data on productivity loss, resource utiliza-
tion associated with direct medical and nonmedical costs) were
collected in the study, while data on prices (e.g., resource unit
costs and labor costs) were collected separately using informa-
tion provided by the Swiss Federal Statistical Ofﬁce or based on
the Swiss standard rates for outpatient medical services (Tarmed
Version alpha-2.2). Because the analysis was done from a soci-
etal perspective, unit costs were calculated regardless of whom
was bearing the costs. Data on consumed quantities of cost
items were collected for all patients during the whole study
period after randomization. Data were collected in case report
forms (CRF) ﬁlled in by the investigator, questionnaires ﬁlled in
by the patients during their visits to the study site, and by
telephone interview with the patient three to four times after the
randomization visit.
Resource utilization data associated with direct medical costs
(primary outcome measure) collected within the study were:
study medication, other GERD-related prescribed medication,
GERD-related over-the-counter (OTC) medication, unscheduled
health-care contacts (visits and telephone contacts) because of
GERD, GERD-related tests and procedures, and GERD-related
hospitalizations. Data on productivity losses were: absence from
work because of GERD and early retirement because of GERD.
Study medication. All study medications were continuously
recorded by the investigator in the CRF.
Other GERD-related prescribed medication: All GERD-
related prescribed medications were continuously recorded by
the investigator and reported in the CRF.
GERD-related OTC medication: At each visit after random-
ization, data on purchased OTC medication since the last visit
(maximum recall period: 30 days) were collected in the CRF
(drug, dose, and quantity). Data on purchased OTC medication
(maximum recall period 30 days) were also collected during
telephone interviews taking place approximately every 5 weeks.
Unscheduled health-care contacts because of GERD: Data
collected at unscheduled study visits to or telephone contacts
with the investigator were entered in the CRF. At each visit after
randomization and at each telephone interview, the following
question was asked: “Has the patient had any contact with
another health-care provider for his/her GERD since last visit?”
If the answer was “yes,” the patient was asked about the number
and type of contact(s) because of GERD, the prescribed GERD-
related medications, and the number and type of GERD-related
tests and procedures.
Health-care visits: At each visit after randomization, it was
assessed whether the contact would have occurred in clinical
practice. The visit was only included in the cost analysis in case the
answer was “yes.”
GERD-related tests and procedures: All GERD-related tests
and procedures were continuously recorded by the investigator in
the CRF.
GERD-related hospitalizations: at each visit after randomiza-
tion, the reason for hospitalization, the duration of hospitaliza-
tion, and the type of ward were collected in case of GERD-related
hospitalizations since last visit.
Absence from work because of GERD: At each visit and at
each telephone interview, data on days absent from work since
the last contact were collected.
Early retirement because of GERD: At the randomization visit
and the completion visit, data on the patients’ employment status
(including early retirement because of GERD) were collected.
Unit cost data. The following resource unit cost data were used:
primary care visit CHF 44.05, primary care telephone contact:
CHF 26.43, specialist visit: CHF 44.05, upper gastrointestinal
endoscopy (without biopsy): CHF 549.50, hospitalization (per
day): CHF 1009, esomeprazole (Nexium) 20 mg (per tablet):
CHF 2.81, and esomeprazole (Nexium) 40 mg (per tablet): CHF
4.06.
Statistical analysis. Direct medical costs (primary outcome vari-
able), as well as direct nonmedical costs and indirect costs (sec-
ondary outcome variables), were calculated, and treatment group
comparisons were based on mean costs per patient. An unad-
justed total direct medical cost per patient was calculated from
the summation of the costs for study medication and other
GERD-related costs, such as for prescribed medication, OTC
medication, unscheduled health-care contacts (visits and tele-
phone contacts), tests and procedures, and hospitalizations,
during the maintenance phase. The adjusted direct medical costs
took into account the length of follow-up for each patient, as
patients who dropped out of the study or were lost to follow-up
were to be included in the analysis. The adjustment attempted to
standardize the cost of each component for each patient to the
intended 26-week follow-up period in the maintenance phase,
assuming linear resource consumption, that is, the costs of clini-
cal outcomes assessed for the follow-up period, were to be
carried forward adjusted for the time left to spend.
A nonparametric analysis test was performed on the
adjusted direct medical costs. The Wilcoxon (rank-sum) test was
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considered to be the most suitable test taking into account the
bimodality of the study medication costs.
A signiﬁcance level of 0.05 was used in statistical tests. Binary
variables were analyzed using the Fisher’s exact test.
For the primary variable and all the secondary variables,
intention-to-treat (ITT) analyses were performed, and presented
as the main results. In the ITT analysis, all the randomized
patients were included, except the patients who received an
unknown study therapy or no study drug at all.
All patients taking at least one dose of the study drug and for
whom postdose information was available were eligible for
safety evaluations, and the results were presented descriptively.
Patient data protection and ethics. The study was conducted
according to International Conference on Harmonisation/Good
Clinical Practice (ICH/GCP) guidelines, and approved by all
institutional ethics committees in the corresponding jurisdictions
in which the study was conducted.
Results
Patient Demographics
Four hundred thirty-nine sites had recruited at least one patient
per site. The ITT population was comprised of 1904 patients
who were properly randomized to the maintenance phase,
having satisﬁed the inclusion and exclusion criteria and having
a known quantity of study drug consumed (refer to Fig. 1:
study ﬂow chart). During 26 weeks, 913 patients received con-
tinuous daily therapy with esomeprazole 20 mg, once daily,
while 991 patients were treated with esomeprazole 20 mg
on-demand. Tables 1 and 2 give an overview of the baseline
patient demographics.
Efﬁcacy and Safety
The majority of patients in each treatment group did not have any
GERD symptoms by the end of the 6-month maintenance phase
(% patients with no symptoms at 6 months; on-demand vs.
continuous: no heartburn: 80 vs. 86%, P < 0.001; no regurgi-
tation: 86 vs. 89%, NS; no epigastric pain: 89% in both groups,
not signiﬁcant). The patients in the on-demand group experienced
slightly more frequently GERD symptoms than those in the
continuous group (Table 3). Fifty-ﬁve (6.0%) patients in the con-
tinuous group experienced a relapse deﬁned as “need for change of
therapy” and received a 4-week treatment course with esomepra-
zole 40 mg q.d. during the maintenance phase compared with 60
(6.1%) patients who were treated on-demand (NS).
No statistically signiﬁcant difference was found regarding the
satisfaction of the patients with the way their heartburn was
treated. At the end of the 6-monthmaintenance phase, 94%of the
patients in the on-demand group and 93% of the patients treated
continuously were classiﬁed as “satisﬁed” (score 1–4) with their
treatment, whereas 74% and 77% of the patients, respectively,
were reported to be “very satisﬁed” (score 1–2) (Wilcoxon rank-
sum test (score 1–7): P < 0.056).
Esomeprazole was generally well tolerated. There were no
tolerability concerns arising from this study, and there were
no clinically relevant differences between the treatment groups
regarding the proﬁle or incidence of adverse events.
2179 patients assessed 
for eligibility
230 excluded
Reasons: not meeting 
inclusion criteria for visit 2 (n 
= 214), others (n = 16) 1935 patients 
randomized
1009 patients allocated 
to on-demand treatment
1009 received allocated 
intervention
926 patients allocated to 
continuous treatment
926 received allocated 
intervention
991 patients analyzed 
18 excluded from analysis 
Reasons: persisting 
symptoms at visit 2 (n = 9), 
unknown quantity of study 
drug used (n = 8), other (n 
= 1) 
913 patients analyzed 
13 excluded from analysis 
Reasons: persisting 
symptoms at visit 2 (n = 7), 
unknown quantity of study 
drug used (n = 6) 
24 screening failures
Reasons: not meeting 
inclusion criteria for visit 1 (n 
= 14), others (n = 10) 
2155 patients
enrolled
Figure 1 Study ﬂow chart.
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Resource Utilization and Cost
Health-care contacts (including hospitalizations and tests and
procedures). Forty-nine percent (484 of 991) of patients ran-
domized to the on-demand regimen had at least one contact with
the investigator that would have occurred as nonprotocol-driven
compared with 46% (420 of 913) of the patients randomized to
the continuous regimen. The majority of contacts were clinic
contacts. The main reason for the contacts was to follow-up the
patient or to reiterate any medication. GERD symptoms were
stated as reason for a nonprotocol-driven visit in only 17% of the
contacts in each treatment group. A further 96 (10%) patients in
the on-demand group and 93 (10%) patients in the continuous
group had additional telephone contact with the investigator
because of GERD during the 6-month maintenance phase.
The mean number of clinic visits to the investigator for any
reason required per patient was 0.52 (SD 0.663) for those in
the on-demand group and 0.50 (SD 0.647) for those in the
continuous group.
The majority of patients did not require any contact with a
specialist health-care provider (SHP) because of GERD, with
only 2% of patients in each treatment group having any contact.
Only ﬁve patients, three in the on-demand treatment group, and
two treated continuously, required hospitalization. Two patients
in the on-demand treatment group and one patient with continu-
ous treatment were hospitalized because of GERD (reasons for
hospitalizations classiﬁed by the investigators as having occurred
because of GERD: fundoplication in one patient and pain
in breast in the other two patients). Table 4 gives a summary
of patients requiring nonprotocol-driven contacts with the
investigator or specialist health-care provider or requiring
hospitalization.
The number of patients requiring an endoscopy (with or
without biopsy), Helicobacter pylori test or pH recording during
the 6-month maintenance phase is summarized by treatment
regimen in Table 5.
Study medication: esomeprazole. The mean number of days on
maintenance therapy in the on-demand group was 177 (SD 38.5;
median: 182) days and 178 (SD 37.0; median: 182) days in the
group on continuous treatment. The consumption of esomepra-
zole 20 mg during the maintenance phase was as follows: mean
number of tablets used in the on-demand group versus continu-
ous: 116 (SD 63.1; median: 100) tablets versus 174 (SD 46.9;
median: 188) tablets. This indicates that the on-demand group
took their medication 4 to 5 days out of a 7-day week, whereas
patients on continuous treatment took their tablets almost daily.
The mean difference of the esomeprazole 20 mg tablet consump-
tion between the on-demand and continuous treatment group is
58 tablets (33%). The majority of the patients randomized to
Table 1 Baseline demographics and GERD symptoms
Variable
Treatment group
On-demand
(n = 991)
Continuous
(n = 913)
Patients
Mean age in years (SD) 54 (14.9) 55 (14.5)
Age range in years 19–88 18–99
Percentage of male patients (NS, chi-square
test: P = 0.064)
48% 53%
Percentage of patients by type of insurance
Basic 58% 58%
Supplementary 42% 42%
Percentage of patients with heartburn by
severity of symptom
Heartburn
None 3% 3%
Mild 14% 15%
Moderate 51% 49%
Severe 32% 34%
Percentage of patients with regurgitation by
severity of symptom
Regurgitation
None 15% 14%
Mild 23% 27%
Moderate 42% 38%
Severe 20% 20%
Percentage of patients with epigastric pain by
severity of symptom
Epigastic pain
None 14% 13%
Mild 23% 22%
Moderate 45% 45%
Severe 19% 20%
Mean number of reﬂux days (SD) 5.6 (1.59) 5.6 (1.54)
GERD, gastroesophageal reﬂux disease; NS, not signiﬁcant.
Table 2 Baseline educational status and employment status
Variable
Treatment group
On-demand
(n = 991)
Continuous
(n = 913)
Percentage of patients by education status
University 5% 5%
Higher professional 11% 12%
Professional school 52% 51%
Grammar school 4% 5%
Basic 28% 26%
Percentage of patients by employment status
Paid employment 53% 51%
Mean hours working per week (SD) 38 (14.4) 38 (14.2)
Retired/pension 33% 37%
Trainee/education 1% 1%
Homemaker/housekeeper 24% 21%
Not employed 5% 5%
Reduction because of GERD 0% 1%
GERD, gastroesophageal reﬂux disease.
Table 3 Summary of GERD symptoms at the end of the 6-month
maintenance phase (LOCF)
Symptoms (Category)
Treatment group
On-demand
(n = 991)
Continuous
(n = 913)
Percentage of patients with heartburn by
severity of symptom
None* 80% 86%
Mild 12% 11%
Moderate 6% 2%
Severe 1% 1%
Percentage of patients with regurgitation by
severity of symptom
None 86% 89%
Mild 9% 8%
Moderate 4% 3%
Severe 1% 1%
Percentage of patients with epigastric pain by
severity of symptom
None 89% 89%
Mild 7% 9%
Moderate 3% 2%
Severe 1% 0%
Mean number of reﬂux days (SD) 0.43 (1.2) 0.37 (1.2)
*P < 0.001.
GERD, gastroesophageal reﬂux disease; LOCF, Last observation carried forward.
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continuous treatment took on average at least one tablet per day.
Less than daily intake was found in most of the patients taking
esomeprazole on-demand, although around one-third of the
patients in the on-demand group took it on average at least one
tablet per day and could not be regarded as adhering to an
on-demand strategy in the proper sense. Figure 2 shows the
distribution of the patients according to the number of tablets
taken per day on esomeprazole.
A post hoc analysis of the baseline demographics was per-
formed, showing that on-demand patients taking at least one
tablet per day had reported signiﬁcantly more severe GERD
symptoms at baseline (Armitage’s chi-square test: heartburn:
P < 0.0001; regurgitation: P = 0.003, epigastric pain: P = 0.032)
than on-demand patients taking their tablets according to the
on-demand strategy, which could have been expected.
Direct medical costs. The difference of the adjusted mean direct
medical costs between the treatment groupswas CHF 88.72 (95%
CI of difference: CHF 41.34–153.95) in favor of the on-demand
treatment strategy (Wilcoxon rank-sum test: P < 0.0001). The
adjusted mean costs are summarized in Table 6. The adjusted
direct medical costs took into account the length of follow-up for
each patient. The adjustment attempted to standardize the cost of
each component for each patient to the intended 26-week
follow-up period in the maintenance phase. The unadjusted direct
medical costs during the 6-month maintenance phase are summa-
rized in Table 7.
Direct nonmedical costs. Travel costs for physician visits were
CHF 3.3 in the on-demand group and CHF 3.0 in the continuous
group. The adjusted direct nonmedical costs were similar in
the two treatment groups (CHF 3.3 vs. 3.0), with the absolute
treatment difference (CHF 0.34) being only a small percentage
compared with the total of the adjusted direct medical costs
(CHF 537.24).
Indirect costs. Indirect costs were assessed by the number of
workdays lost because of GERD (as a measure of productivity
loss) and by leisure time spent attending physicians visit. The loss
of working time and the time lost because of nonprotocol-driven
physician visits because of GERD during the 6-month mainte-
nance phase is summarized in Table 8. There was no difference
between the groups with respect to indirect costs.
Only 27 patients, 15 from the on-demand treatment and 12
from the continuous group, reported having any time off work
because of GERD. From those 15 patients in the on-demand
group who required time off work, the average number of days
absent was 4.9 (range 1–14 days, SD 5.22) and the correspond-
ing mean number of days off work because of GERD for the 12
patients in the continuous group were 4.9 days (range 1–14 days,
SD 4.06). Only 12 of the 15 in the on-demand group and 7 of the
12 in the continuous group had supplied information on the
number of hours worked per week at screening; hence, the study
had information on hours absent from work.
Discussion
The purpose of this study was to compare the costs and efﬁcacy
of an on-demand therapy and a continuous therapy with esome-
prazole 20 mg from a general practice point of view in patients
with GERD symptoms after having achieved initial symptom
relief with esomeprazole 40 mg once-daily in Switzerland. The
primary variable for this study was the difference in mean direct
medical costs between on-demand and continuous treatment
with esomeprazole 20 mg during the 6-month maintenance
phase.
The difference of the adjusted mean direct medical costs
between the treatment groups was CHF 88.72 (95% CI: CHF
41.34–153.95) in favor of the on-demand treatment strategy
(Wilcoxon rank-sum test: P < 0.0001). Adjusted direct nonmedi-
cal costs and the productivity loss were similar in both treatment
groups during the 6-month maintenance phase. Hence, health-
care payers will obtain net savings by implementing the use of
on-demand esomeprazole.
Certain limitations of this study are noteworthy. First, the
concomitant collection of economic data alongside clinical trials
is not without problems [12]. Because the study protocol dictates
much of the resource use, it is imperative to collect the patients’
use of resources outside of the scope of the trial. This may lead to
a certain imprecision of the data and may introduce some bias
[13]. Nevertheless, with appropriate data collection techniques
(e.g., telephone maintenances and patient diaries), the precision
may well be improved. Second, we used mainly charge data as a
Table 4 Summary of number of patients requiring nonprotocol-driven
contact with investigator or specialist health-care provider or requiring
hospitalization
Resource
Treatment group
On-demand
(n = 991)
Continuous
(n = 913)
Number of patients requiring investigator
contacts by type of contact
Any contact 484 420
Clinic visit 431 381
Telephone 40 40
Additional telephone* 96 93
Number of patients requiring SHP contacts
because of GERD by type of contact
Any SHP contact 24 17
SHP clinic 22 13
SHP telephone 2 3
SHP other 0 3
Number of patients requiring
hospitalization by typo of hospitalization and
number of admissions
Any hospitalization 3 2
GERD hospitalization† 2 1
GERD ICU admissions 1 0
GERD GW admissions
0 989 912
1 1 1
2 1 0
Mean days in ICU (SD) 0.012 (0.38) 0.0 (0.0)
Mean days in GW (SD) 0.027 (0.67) 0.001 (0.03)
*Because of GERD.
†Reasons for hospitalization: on-demand group: “fundoplication” (one patient), “pain in
breast” (one patient); continuous group: “pain in breast” (one patient).
GERD, gastroesophageal reﬂux disease; GW, general ward; ICU, intensive care unit; SHP,
Specialist health-care provider.
Table 5 Number of patients requiring GERD-related test procedures
during the 6-month maintenance phase
Resource
Treatment group
On-demand
(n = 991)
Continuous
(n = 913)
Endoscopy without biopsy 9 7
Endoscopy with biopsy 19 21
Helicobacter pylori test 22 18
pH recording 2 3
GERD, gastroesophageal reﬂux disease.
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proxy for costs [14]. Because true economic costs (i.e., opportu-
nity costs at the margin of production) are not readily and
publicly available in Switzerland, we were urged to use charge
data. Based on our experience, however, we feel conﬁdent that
these charges reﬂect true costs to a great extent. A last limitation
is the potential for a bias induced by the physicians. We can not
exclude the possibility that because of the very fact that this was
a prospective health economic study, physicians and patients
were inclined to reduce the amount of resource utilization
because of behavioral changes. This bias can usually only be
prevented by conducting retrospective analyses, which obviously
have other signiﬁcant drawbacks.
It is also important to consider that from a patient’s perspec-
tive, the effectiveness of treatment is likely to be of paramount
importance. Effective treatment generally leads to greater satis-
faction with treatment, improved quality of life, and a more
rapid return to work [15–17]. One of the limitations of this study
is that it is not known how effectively the endoscopic healing of
reﬂux esophagitis in patients who had this abnormality at base-
line was maintained. It was shown in a previous study that
symptom-driven maintenance treatment would not adequately
achieve the objective of maintaining healed reﬂux esophagitis
across all Los Angeles classiﬁcation grades [18]. The proportion
of relapses increased over time, and in the current Swiss series,
nothing is known about the development of esophageal erosions
within the 6-months study period or after. In addition, about
one-third of patients took their medication every day in the
on-demand treatment arm, showing that there is a patient popu-
lation who needs continuous treatment. This is also one of the
explanations why there is little difference in study drug utiliza-
tion between the two groups, and this could have resulted in
fewer than expected episodes of resource utilization by the
0
50
100
150
200
250
300
350
400
0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1 1.1 1.2 1.3 1.4 1.5 1.6 1.7 1.8 1.9 2 2.1 2.2
Tablets per days on esomeprazole
N
um
be
r 
of
 p
at
ie
nt
s
Continuous
On-demand
Figure 2 Distribution of patients according to
the number of tablets taken per day on esome-
prazole during maintenance phase.
Table 6 Overview of adjusted mean costs in CHF per patient
Resource
Treatment group
On-demand
(n = 991)
Continuous
(n = 913)
Total direct medical costs* 494.6 (1624) 583.5 (243.1)
Unscheduled health-care contacts† (SD) 38.2 (70.8) 39.0 (109.1)
Hospitalizations† (SD) 61.2 (1571) 1.1 (34.0)
Tests and procedures† (SD) 33.1 (262.3) 26.1 (155.7)
Study drugs: esomeprazole (20 mg and
40 mg) (SD)
352.7 (181.0) 509.4 (97.6)
Prescribed medication† (SD) 8.8 (55.3) 7.1 (40.2)
OTC medication (SD) 0.7 (4.6) 0.9 (8.2)
Direct nonmedical costs
Transportation costs (SD) 3.3 (12.6) 3.0 (10.3)
Indirect costs
Mean days off work† (SD) 4.9 (5.2) 4.9 (4.1)
*Wilcoxon rank-sum test: P < 0.0001.
†Because of GERD.
GERD, gastroesophageal reﬂux disease; OTC, over-the-counter.
Table 7 Mean unadjusted direct medical costs in CHF during the
6-month maintenance phase
Resource
Treatment group
On-demand
(n = 991)
Continuous
(n = 913)
Unscheduled health-care contacts* (SD) 32.4 (43.7) 30.7 (42.1)
Hospitalizations* (SD) 39.7 (1050) 1.1 (33.4)
Tests and procedures* (SD) 21.2 (123.5) 23.3 (134.9)
Study drugs: esomeprazole (20 and
40 mg) (SD)
334.1 (176.8) 496.8 (114.6)
Prescribed medication* (SD) 6.1 (33.3) 4.8 (23.4)
OTC medication* (SD) 0.6 (4.1) 0.8 (5.4)
Total direct medical costs*† (SD) 434.1 (1075) 557.6 (200.3)
*Because of GERD.
†Wilcoxon rank-sum test: P < 0.0001.
GERD, gastroesophageal reﬂux disease; OTC, over-the-counter.
Table 8 Indirect costs: loss of working time because of
GERD and time loss because of physicians visits in the 6-month main-
tenance phase
Resource
Treatment group
On-demand
(n = 991)
Continuous
(n = 913)
Loss of working time because of GERD
Number of patients absent from work 15 12
Mean time loss because of physician visits
Total number of contacts (SD) 0.60 (0.8) 0.55 (0.7)
Visit time at physician, hours (SD) 0.7 (0.9) 0.6 (0.8)
Absence from work, hours (SD) 0.1 (0.5) 0.1 (0.7)
Leisure time lost, hours (SD) 0 (0.2) 0 (0.5)
GERD, gastroesophageal reﬂux disease.
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on-demand group. Furthermore, symptoms of GERD have been
shown to have a signiﬁcant impact on productivity while at
work, as well as while carrying out regular daily activities other
than work [19,20]. Nevertheless, instruments for prospectively
assessing patient-reported reduced productivity were not
included in the current study, because these were not considered
appropriate as a basis for cost calculations in a long-term study
because of their short recall period.
The consumption of esomeprazole 20 mg during the mainte-
nance phase in the on-demand group was higher in our study
(one tablet on 4–5 days out of a 7-day week) than reported by
Talley et al. (one tablet every third day) [21]. In our study, the
study drug dispensation from physician to patient was at the
discretion of the investigator, i.e., it was possible that patients
would receive the whole supply (200 tablets) at randomization.
This supply would have covered more than a daily intake of
esomeprazole 20 mg in the on-demand arm. This generous access
to free medication could be one explanation for the difference
seen in our results compared with the ones reported by Talley
et al. Furthermore, the drug consumptions were assessed differ-
ently in the two studies: drug containers registering date and time
for each opening and closure of the container were used in the
study of Talley et al. Drug consumption was then calculated as
the number of openings. In our study, the drug consumption was
calculated from dispensed and returned study medication, i.e.,
tablets not returned were counted as consumed, which could lead
to an overestimation of the drug consumption. Another differ-
ence between these two trials concerns the study population. In
our study, uninvestigated, symptomatic GERD patients were
included, while Talley et al. performed their study in GERD
patients proven to be endoscopically negative.
There was a difference between treatment arms in patient
numbers assigned to each arm. There could be different expla-
nations for this, but one contribution to this imbalance might be
that the randomization was planned on the assumption that sites
would recruit four patients or an exact multiple of four (two
patients per kit of four to be treated on-demand, the other two
continuously). In fact, only 33% of the sites recruited four
patients or an exact multiple of four patients.
To the best of our knowledge, this is the ﬁrst prospective cost
analysis of managing patients with GERD with the two preven-
tive treatment options in everyday clinical practice in Switzer-
land. These results conﬁrm that the maintenance therapy through
6 months with respect to patients’ satisfaction and symptom
control, deﬁned as no need for change of therapy, can be per-
formed with a continuous, as well as by an on-demand schedule
using esomeprazole 20 mg daily. The treatment with continuous
esomeprazole was more efﬁcient than the on-demand therapy
with regard to remission of heartburn. This was, however,
expected because of the nature of the on-demand therapy where
patients were instructed to take their tablets when they
had symptoms. The adjusted direct medical costs of a 6-month
on-demand treatment with esomeprazole 20 mg in patients with
GERD were signiﬁcantly lower compared with a continuous
treatment with esomeprazole 20 mg once a day. The slightly
increased efﬁciency of the continuous treatment regarding heart-
burn remission needs to be balanced against the higher costs
associated with that treatment strategy. It is difﬁcult to draw a
conclusion about which of the esomeprazole treatment strategies
are cost-effective relative to the other. Because the on-demand
therapy does not lead to more frequent need for change of
therapy because of insufﬁcient symptom control for the patients,
it represents a cost-saving alternative to the continuous treatment
strategy with esomeprazole. Nevertheless, the long-term efﬁcacy
and safety of such an approach has yet to be documented.
Source of ﬁnancial support: The study was supported by AstraZeneca AG
Switzerland.
References
1 Moher D, Schulz KF Altman DG for The CONSORT Group. The
CONSORT statement: revised recommendations for improving
the quality of reports of parallel-group randomized trials. Ann
Intern Med 2001;134:657–62.
2 Altman DG, Schulz KF, Moher D, et al. The revised CONSORT
statement for reporting randomized trials: explanation and elabo-
ration. Ann Intern Med 2001;134:663–94.
3 Schwenkglenks M, Marbet UA, Szucs TD. Gastroesophageal
reﬂux in Switzerland A population-based study. Soz Praven-
tivmed 2004;49:51–61.
4 Röhss K, Lind T, Wilder-Smith C. Esomeprazole 40 mg provides
more effective intragastric acid control than lansoprazole 30 mg,
omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg
in patients with gastroesophageal reﬂux symptoms. Eur J Clin
Pharmacol 2004;60:531–9.
5 Miner P, Katz PO, Chen Y, et al. Gastric acid control with esome-
prazole, lansoprazole, omeprazole, pantoprazole and rabepra-
zole: a ﬁve-way crossover study. Am J Gastroenterol 2003;98:
2616–20.
6 Miner P, Katz PO, Chen Y, et al. Reanalysis of intragastric pH
results based on updated correction factors for Slimline® and
Zinetics™ 24 single-use pH catheters. Am J Gastroenterol 2006;
101:404–5.
7 Kahrilas PJ, Falk GW, Johnson DA, et al. Esomeprazole improves
healing and symptom resolution as compared with omeprazole in
reﬂux oesophagitis patients: a randomized controlled trial.
Aliment Pharmacol Ther 2000;14:1249–58.
8 Richter JE, Kahrilas PJ, Johanson J, et al. Efﬁcacy and safety of
esomeprazole compared with omeprazole in GERD patients with
erosive esophagitis: a randomized controlled trial. Am J Gastro-
enterol 2001;96:656–65.
9 Castell DO, Kahrilas PJ, Richter JE, et al. Esomeprazole (40 mg)
compared with lansoprazole (30 mg) in the treatment of erosive
esophagitis. Am J Gastroenterol 2002;97:575–83.
10 Labenz J, Armstrong D, Lauritsen K, et al. A randomized com-
parative study of esomeprazole 40 mg versus pantoprazole 40 mg
for healing erosive oesophagitis: the EXPO study. Aliment
Pharmacol Ther 2005;21:739–46.
11 Luce BR, Elixhauser A. Assessing costs. In: Culyer AJ, ed. Stan-
dards for Socioeconomic Evaluation of Health Care Products
and Services. Berlin and Heidelberg: Springer-Verlag, 1990:56–
67.
12 Ramsey S, McIntosh M, Sullivan D. Design issues for conducting
cost-effectiveness analyses alongside clinical trials. Annu Rev
Public Health 2001;22:129–41.
13 Donaldson C, Hundley V, Mcintosh E. Using Economics along-
side clinical trials: why we cannot choose the Evaluation tech-
nique in advance? Health Econ 1996;5:267–9.
14 Finkler SA. The distinction between costs and charges. Ann Intern
Med 1982;96:102–9.
15 Wiklund I, Bardhan KD, Müller-Lissner S, et al. Quality of life
during acute and intermittent treatment of gastroesophageal
reﬂux disease with omeprazole compared with ranitidine. Results
from a multi-center clinical trial. Ital J Gastroenterol Hepatol
1998;30:19–27.
16 Rush DR, Stelmach WJ, Young TL, et al. Clinical effectiveness
and quality of life with ranitidine vs placebo in gastrooesophageal
reﬂux disease patients: a clinical experience network (CEN)
study. J Fam Pract 1995;41:126–36.
17 Revicki DA, Wood M, Maton PN, et al. The impact of gastroe-
sophageal reﬂux disease on health-related quality of life. Am J
Med 1998;104:252–8.
18 Sjöstedt S, Befrits R, Sylvan A, et al. Daily treatment with esome-
prazole is superior to that taken on-demand for maintenance of
healed erosive oesophagitis. Aliment Pharmacol Ther 2005;22:
183–91.
280 Szucs et al.
19 Henke CJ, Levin TR, Henning JM, et al. Work loss costs due to
peptic ulcer disease and gastroesophageal reﬂux disease in a
health maintenance organization. Am J Gastroenterol 2000;95:
788–92.
20 Wahlqvist P, Carlsson J, Stålhammar NO, et al. Validity of a
work productivity and activity impairment questionnaire for
patients with symptoms of gastro-esophageal reﬂux disease
(WPAI-GERD)—results from a cross-sectional study. Value
Health 2002;5:106–13.
21 Talley NJ, Venables TL, Green JRB, et al. Esomeprazole 40 mg
and 20 mg is efﬁcacious in the long-term management of patients
with endoscopy-negative gastro-oesophageal reﬂux disease: a
placebo-controlled trial of on-demand therapy for 6 months. Eur
J Gastroenterol Hepatol 2002;14:857–63.
Cost-Effectiveness of Esomeprazole in GERD 281
